Work

The role of transcription factor Runx2 in tumor infiltrating T cells

Year: 2013

Type: article

Abstract: Meeting abstracts Adoptive T cell therapy (ACT) is a promising treatment for melanoma patients with a clinical response rate of about 50%. However, half of patients treated do not respond to this therapy, underlining the need for improvement . One of the limitations of ACT is the poor effector

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-1-s1-p23

Authors: Rina Mbofung, Weiyi Peng, Chengwen Liu, Chunyu Xu, Shruti Malu, Yan Yang, Wencai Ma, Zhiqiang Wang, Willem Overwijk, Eric Davis, Brendan Lee, Patrick Hwu

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston, Baylor College of Medicine

Language: English

Topic: T-cell and B-cell Immunology

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2065344414

FWCI:

Cites:

Cited by:

Related to: 10